Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
CASE Comprehensive Cancer Center, Cleveland, Ohio;
University of Pittsburgh Medical Center, Pittsburgh, Pa
Background: Epidermal growth factor receptor (EGFR) is highly expressed in squamous cell cancer of the head and neck (SCCHN), representing a promising therapeutic target. Erlotinib (E) is an EGFR tyrosine kinase inhibitor that may potentiate the efficacy of concurrent radiation (RT) and docetaxel (D). We sought to establish the maximum tolerated dose, toxic effects, and preliminary efficacy of the combination of RT, D and E in patients with SCCHN.
Savvides PS, Agarwala SS, Greskovich J, et al. P001 Phase 1 Study of Erlotinib, Docetaxel, and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck. Arch Otolaryngol Head Neck Surg. 2006;132(8):865. doi:10.1001/archotol.132.8.865-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: